Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

794 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A tool for predicting the outcome of reperfusion in ST-elevation myocardial infarction using age, thrombotic burden and index of microcirculatory resistance (ATI score).
De Maria GL, Fahrni G, Alkhalil M, Cuculi F, Dawkins S, Wolfrum M, Choudhury RP, Forfar JC, Prendergast BD, Yetgin T, van Geuns RJ, Tebaldi M, Channon KM, Kharbanda RK, Rothwell PM, Valgimigli M, Banning AP. De Maria GL, et al. Among authors: valgimigli m. EuroIntervention. 2016 Nov 20;12(10):1223-1230. doi: 10.4244/EIJV12I10A202. EuroIntervention. 2016. PMID: 27866132 Free article.
The 5-year clinical outcomes after a randomized comparison of sirolimus-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction.
Tebaldi M, Arcozzi C, Campo G, Percoco G, Ferrari R, Valgimigli M; STRATEGY Investigators. Tebaldi M, et al. Among authors: valgimigli m. J Am Coll Cardiol. 2009 Nov 10;54(20):1900-1. doi: 10.1016/j.jacc.2009.08.009. J Am Coll Cardiol. 2009. PMID: 19892243 Free article. No abstract available.
Safety evaluation of tirofiban.
Valgimigli M, Tebaldi M. Valgimigli M, et al. Expert Opin Drug Saf. 2010 Sep;9(5):801-19. doi: 10.1517/14740338.2010.507189. Expert Opin Drug Saf. 2010. PMID: 20670206 Review.
Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction.
Sabaté M, Cequier A, Iñiguez A, Serra A, Hernández-Antolín R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vázquez N, Brugaletta S, Backx B, Serruys P. Sabaté M, et al. Among authors: valgimigli m. EuroIntervention. 2011 Dec;7(8):977-84. doi: 10.4244/EIJV7I8A154. EuroIntervention. 2011. PMID: 22115622 Free article. Clinical Trial.
Does the site of bleeding matter? A stratified analysis on location of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarction.
Vranckx P, Campo G, Anselmi M, Bolognese L, Colangelo S, Biondi-Zoccai G, Moreno R, Piva T, Favero L, Prati F, Nazzaro M, Díaz Fernández JF, Ferrari R, Valgimigli M; Multicenter Evaluation of Single High-Dose Bolus Tirofiban vs. Abciximab with Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study. Vranckx P, et al. Among authors: valgimigli m. EuroIntervention. 2012 May 15;8(1):71-8. doi: 10.4244/EIJV8I1A12. EuroIntervention. 2012. PMID: 22311867 Free article. Clinical Trial.
Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.
Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, Parrinello G, Ferrari R; FABOLUS PRO Investigators. Valgimigli M, et al. JACC Cardiovasc Interv. 2012 Mar;5(3):268-77. doi: 10.1016/j.jcin.2012.01.006. JACC Cardiovasc Interv. 2012. PMID: 22440491 Free article. Clinical Trial.
Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY).
Valgimigli M, Borghesi M, Tebaldi M, Vranckx P, Parrinello G, Ferrari R; PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY Investigators. Valgimigli M, et al. Eur Heart J. 2013 Mar;34(12):909-19. doi: 10.1093/eurheartj/ehs460. Epub 2013 Jan 12. Eur Heart J. 2013. PMID: 23315904 Clinical Trial.
Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).
Campo G, Tebaldi M, Vranckx P, Biscaglia S, Tumscitz C, Ferrari R, Valgimigli M. Campo G, et al. Among authors: valgimigli m. J Am Coll Cardiol. 2014 Feb 18;63(6):506-12. doi: 10.1016/j.jacc.2013.09.043. Epub 2013 Oct 23. J Am Coll Cardiol. 2014. PMID: 24161321 Free article. Clinical Trial.
794 results